|
|
|
 |
 |
||||||
Melior Discovery scientific advisors April 2009 Melior Discovery Newsletter Other Articles: Available murine models of Alzheimer’s disease rely solely upon the supernormal expression of amyloid precursor protein (APP) which is not predictive of the human condition. In addition, available models exhibit exponential plaque deposition kinetics which may confound efforts to identify drug candidate efficacy. Melior’s proprietary huAβ mouse model is capable of reliably and predictably assessing plaque deposition relevant to the progression of human Alzheimer’s disease. Melior’s neuroTRACEdg platformprovides the addition of Melior Discovery’s complementary behavioral models, so that improvement of cognitive deficits in Alzheimer’s disease can be effectively evaluated. In addition to the theraTRACE® indications discovery platform and a proprietary Alzheimer’s disease model, Melior is able to extend its high throughput pharmacology approach to customized in vivo efficacy evaluations in other focused therapeutic areas. Melior has established expertise in the following major therapeutic areas:
Download the Alzheimer's Model data sheet Other articles:
|
|
